

# Karen Pulford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3827193/publications.pdf>

Version: 2024-02-01

70  
papers

6,958  
citations

126708

33  
h-index

106150

65  
g-index

70  
all docs

70  
docs citations

70  
times ranked

6587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoma versus Carcinoma and Other Collaborations. <i>Cells</i> , 2022, 11, 174.	1.8	0
2	Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma. <i>Clinical Immunology</i> , 2018, 195, 77-81.	1.4	7
3	Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients. <i>Advances in Hematology</i> , 2017, 2017, 1-9.	0.6	2
4	Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. <i>Journal of Cancer</i> , 2016, 7, 1383-1387.	1.2	11
5	The European antibody network's practical guide to finding and validating suitable antibodies for research. <i>MAbs</i> , 2016, 8, 27-36.	2.6	46
6	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. <i>PLoS ONE</i> , 2015, 10, e0140483.	1.1	13
7	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0125203.	1.1	30
8	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. <i>Biomarker Insights</i> , 2014, 9, BMI.S16553.	1.0	7
9	An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. <i>Cancer Immunity</i> , 2013, 13, 16.	3.2	10
10	RNASSET2 " An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. <i>Journal of Proteomics</i> , 2012, 75, 5279-5292.	1.2	9
11	Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens. <i>PLoS ONE</i> , 2011, 6, e23916.	1.1	10
12	CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2011, 96, 78-86.	1.7	10
13	Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 534-543.	1.2	14
14	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
15	Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. <i>Blood</i> , 2010, 115, 3314-3319.	0.6	111
16	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. <i>Cancer Immunity</i> , 2010, 10, 8.	3.2	33
17	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 396-407.	1.2	29
18	Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 1023-1028.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S23-S24.	1.4	1
20	Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration. <i>Pediatric Blood and Cancer</i> , 2008, 50, 879-881.	0.8	12
21	Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 672-675.	1.2	1,570
22	A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1511-1520.	1.5	36
23	Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. <i>Blood</i> , 2008, 111, 2816-2824.	0.6	89
24	CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell Lymphoma. <i>Cancer Research</i> , 2007, 67, 1898-1901.	0.4	38
25	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. <i>Blood</i> , 2007, 110, 2600-2609.	0.6	34
26	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2007, 138, 479-486.	1.2	28
27	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. <i>Molecular Cancer</i> , 2006, 5, 18.	7.9	74
28	PASD1 is a potential multiple myeloma-associated antigen. <i>Blood</i> , 2006, 108, 3953-3955.	0.6	21
29	B and CTL responses to the ALK protein in patients with ALK-positive ALCL. <i>International Journal of Cancer</i> , 2006, 118, 688-695.	2.3	58
30	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. <i>International Journal of Cancer</i> , 2006, 118, 3161-3166.	2.3	44
31	Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca <sup>2+</sup> -dependent association with annexin VI. <i>Blood</i> , 2005, 105, 2812-2820.	0.6	41
32	Antibody Techniques Used in the Study of Anaplastic Lymphoma Kinase-Positive ALCL. , 2005, 115, 271-294.		4
33	Protein Expression Profiles Confirm PASD1 as a Cancer Testis Antigen and a Potential Candidate for Lymphoma Immunotherapy.. <i>Blood</i> , 2005, 106, 2825-2825.	0.6	1
34	Serologic detection of diffuse large B-cell lymphoma-associated antigens. <i>International Journal of Cancer</i> , 2004, 110, 563-569.	2.3	24
35	Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. <i>Lancet Oncology</i> , The, 2004, 5, 127-128.	5.1	16
36	Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. <i>British Journal of Haematology</i> , 2003, 120, 671-678.	1.2	13

#	ARTICLE	IF	CITATIONS
37	Expression of B-Lymphocyte-Associated Transcription Factors in Human T-Cell Neoplasms. American Journal of Pathology, 2003, 162, 861-871.	1.9	37
38	Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas. American Journal of Pathology, 2002, 160, 1487-1494.	1.9	102
39	Immunochemical studies of antigenic lymphoma-associated proteins. British Journal of Haematology, 2002, 116, 135-141.	1.2	7
40	Anaplastic lymphoma kinase proteins and malignancy. Current Opinion in Hematology, 2001, 8, 231-236.	1.2	32
41	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. Laboratory Investigation, 2001, 81, 419-426.	1.7	158
42	Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27Kip1. Oncogene, 2001, 20, 4466-4475.	2.6	26
43	Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 2000, 95, 3204-3207.	0.6	224
44	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, 2000, 96, 1605-1607.	0.6	103
45	Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma. American Journal of Pathology, 2000, 156, 1711-1721.	1.9	197
46	Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 2000, 95, 3204-3207.	0.6	9
47	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, 2000, 96, 1605-1607.	0.6	4
48	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. Blood, 1999, 94, 3265-3268.	0.6	266
49	t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma. Blood, 1999, 94, 362-364.	0.6	86
50	A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation. Blood, 1999, 93, 3088-3095.	0.6	288
51	Immunohistochemical screening for oncogenic tyrosine kinase activation. , 1999, 187, 588-593.		14
52	Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma. American Journal of Pathology, 1999, 154, 1657-1663.	1.9	53
53	Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. Journal of Leukocyte Biology, 1999, 65, 841-845.	1.5	53
54	Immunohistochemical screening for oncogenic tyrosine kinase activation. Journal of Pathology, 1999, 187, 588-593.	2.1	1

#	ARTICLE	IF	CITATIONS
55	A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation. <i>Blood</i> , 1999, 93, 3088-3095.	0.6	104
56	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. , 1998, 186, 140-143.		107
57	TAL1 expression does not occur in the majority of T-ALL blasts. <i>British Journal of Haematology</i> , 1998, 102, 449-457.	1.2	18
58	ALK Expression Defines a Distinct Group of T/Null Lymphomas (â€œALK Lymphomasâ€) with a Wide Morphological Spectrum. <i>American Journal of Pathology</i> , 1998, 153, 875-886.	1.9	255
59	ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of Morphology. <i>Blood</i> , 1998, 91, 2076-2084.	0.6	491
60	Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1. <i>Blood</i> , 1997, 89, 1394-1404.	0.6	524
61	A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation. <i>Blood</i> , 1997, 89, 1483-1490.	0.6	320
62	Retrovirus-Mediated Gene Transfer of NPM-ALK Causes Lymphoid Malignancy in Mice. <i>Blood</i> , 1997, 90, 2901-2910.	0.6	250
63	The t(2;5);associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. <i>Journal of Cutaneous Pathology</i> , 1997, 24, 597-603.	0.7	50
64	Anaplastic Large Cell Lymphoma of Maternal Origin Involving the Placenta: Case Report and Literature Survey. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1236-1241.	2.1	49
65	A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation. <i>Blood</i> , 1997, 89, 1483-1490.	0.6	8
66	AN IMMUNOHISTOCHEMICAL STUDY OF TALâ€1 PROTEIN EXPRESSION IN LEUKAEMIAS AND LYMPHOMAS WITH A NOVEL MONOCLONAL ANTIBODY, 2TL 242. <i>Journal of Pathology</i> , 1996, 178, 311-315.	2.1	1
67	Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. <i>Cytometry</i> , 1992, 13, 502-509.	1.8	83
68	Cervical wart virus infection, intraepithelial neoplasia and carcinoma; an immunohistological study using a panel of monoclonal antibodies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1983, 90, 1069-1081.	1.1	18
69	Diagnosis of Human Lymphoma with Monoclonal Antileukocyte Antibodies. <i>New England Journal of Medicine</i> , 1983, 309, 1275-1281.	13.9	376
70	ALK: Anaplastic lymphoma kinase. , 0, , 162-189.		1